169 related articles for article (PubMed ID: 33942253)
1. Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases.
Chao X; Tan W; Tsang JY; Tse GM; Hu J; Li P; Hou J; Li M; He J; Sun P
Breast Cancer; 2021 Sep; 28(5):1100-1111. PubMed ID: 33942253
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Leo F; Bartels S; Mägel L; Framke T; Büsche G; Jonigk D; Christgen M; Lehmann U; Kreipe H
Virchows Arch; 2016 Aug; 469(2):191-201. PubMed ID: 27220763
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
[TBL] [Abstract][Full Text] [Related]
4. Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.
Beca F; Sebastiao APM; Pareja F; Dessources K; Lozada JR; Geyer F; Selenica P; Zeizafoun N; Wen HY; Norton L; Brogi E; Weigelt B; Reis-Filho JS
Histopathology; 2020 Aug; 77(2):321-326. PubMed ID: 32043609
[TBL] [Abstract][Full Text] [Related]
5. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Bartels S; van Luttikhuizen JL; Christgen M; Mägel L; Luft A; Hänzelmann S; Lehmann U; Schlegelberger B; Leo F; Steinemann D; Kreipe H
J Pathol; 2018 Jul; 245(3):373-383. PubMed ID: 29708279
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract][Full Text] [Related]
8. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases.
Carter MR; Hornick JL; Lester S; Fletcher CD
Am J Surg Pathol; 2006 Mar; 30(3):300-9. PubMed ID: 16538049
[TBL] [Abstract][Full Text] [Related]
9. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
11. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Metaplastic Breast Cancer Successfully Treated with Adriamycin and Cisplatin.
Hayashino K; Zaitsu J; Kuraoka K; Hirata T
Intern Med; 2023 Feb; 62(4):655-659. PubMed ID: 35908970
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Features of Metaplastic Breast Carcinoma: Experience From a Tertiary Cancer Center of North India.
Damera VV; Chowdhury Z; Tripathi M; Singh R; Verma RK; Jain M
Cureus; 2022 Sep; 14(9):e28978. PubMed ID: 36237767
[TBL] [Abstract][Full Text] [Related]
14. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
[TBL] [Abstract][Full Text] [Related]
15. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors on outcomes in metaplastic breast cancer.
Leyrer CM; Berriochoa CA; Agrawal S; Donaldson A; Calhoun BC; Shah C; Stewart R; Moore HCF; Tendulkar RD
Breast Cancer Res Treat; 2017 Oct; 165(3):499-504. PubMed ID: 28689362
[TBL] [Abstract][Full Text] [Related]
17. [Matrix-producing breast carcinoma with myoepithelial differentiation--description of 11 cases and review of literature aimed at histogenesis and differential diagnosis].
Kinkor Z; Boudová L; Ryska A; Kajo K; Svec A
Ceska Gynekol; 2004 May; 69(3):229-36. PubMed ID: 15310000
[TBL] [Abstract][Full Text] [Related]
18. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
19. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Freitag CE; Mei P; Wei L; Parwani AV; Li Z
Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]